$CHEV
Charging Robotics Inc. Stock $chev

$chev Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023068190 Filed on August 16, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$127.0K
YoY Change
% of Gross Profit
Research & Development	$145.0K	$37.00K
YoY Change	-31.92%	-75.5%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$145.0K	$37.00K
YoY Change	290.81%	161.47%
Operating Profit	-$272.0K	-$181.0K
YoY Change	633.11%	1179.06%
Interest Expense	-$14.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$286.0K	-$181.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$286.0K	-$191.0K
YoY Change	670.85%	1244.6%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	1.373B shares	1.221B shares	256.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$111.0K
YoY Change
Cash & Equivalents	$111.0K	$254.0K	$107.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$157.0K	$301.0K	$107.1K
YoY Change	44.1%	311.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$85.00K	$85.00K	$74.00K
YoY Change			0.0%
Long-Term Investments	$106.0K
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$252.0K	$279.0K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$157.0K	$301.0K	$107.1K
Total Long-Term Assets	$252.0K	$279.0K	$0.00
Total Assets	$409.0K	$580.0K	$107.1K
YoY Change	275.4%	692.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$74.00K		$52.14K
YoY Change	170.07%		176.52%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$190.0K	$138.0K	$55.14K
YoY Change	-0.21%	17.42%	192.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00
YoY Change
Other Long-Term Liabilities	$49.00K
YoY Change
Total Long-Term Liabilities	$49.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$190.0K	$138.0K	$55.14K
Total Long-Term Liabilities	$49.00K
Total Liabilities	$239.0K	$187.0K	$55.14K
YoY Change	25.53%	59.12%	192.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.716M	-$1.504M	-$1.660M
YoY Change	5.92%	-4.99%	6.56%
Common Stock	$1.818M	$137.0K	$31.44K
YoY Change	6981.09%	433.61%	22.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$170.0K	$393.0K	$51.92K
YoY Change
Total Liabilities & Shareholders Equity	$409.0K	$580.0K	$107.1K
YoY Change	275.4%	692.61%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$286.0K	-$191.0K
YoY Change	670.85%	1244.6%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$511.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$3.000K
YoY Change
Cash From Investing Activities	$3.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$500.5K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	591.0K
YoY Change
NET CHANGE
Cash From Operating Activities	-511.0K
Cash From Investing Activities	3.000K
Cash From Financing Activities	591.0K
Net Change In Cash	83.00K
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$511.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56253
	dei	Entity Registrant Name EntityRegistrantName	FUEL DOCTOR HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2274999
	dei	Entity Address Address Line1 EntityAddressAddressLine1	20 Raul Wallenberg Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv
	dei	Entity Address Country EntityAddressCountry	IL
	dei	City Area Code CityAreaCode	(647)
	dei	Local Phone Number LocalPhoneNumber	558-5564
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1372656029	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	254000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27000	usd
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	47000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	71000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	301000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98000	usd
CY2023Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	133000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	152000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	85000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74000	usd
CY2023Q2	fdoc	Shareholder Loan ShareholderLoan	61000	usd
CY2022Q4	fdoc	Shareholder Loan ShareholderLoan	60000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	279000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	286000	usd
CY2023Q2	us-gaap	Assets Assets	580000	usd
CY2022Q4	us-gaap	Assets Assets	384000	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	50000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	108000	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	66000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	595000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	138000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	703000	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	187000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	752000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1372656029	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1372656029	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27273	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27273	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	137000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1681000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	741000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-19000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-12000	usd
CY2023Q2	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	98000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	91000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1504000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1188000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	393000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-368000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	580000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	384000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	151000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	149000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	364000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	144000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	156000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-181000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-183000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-305000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-456000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-181000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-183000	usd
	us-gaap	Profit Loss ProfitLoss	-305000	usd
	us-gaap	Profit Loss ProfitLoss	-456000	usd
CY2023Q2	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-10000	usd
CY2022Q2	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-5000	usd
	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-11000	usd
	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-9000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-191000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-188000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-316000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-465000	usd
CY2023Q2	us-gaap	Oci Equity Method Investment After Tax OciEquityMethodInvestmentAfterTax	-7000	usd
CY2022Q2	us-gaap	Oci Equity Method Investment After Tax OciEquityMethodInvestmentAfterTax	-19000	usd
	us-gaap	Oci Equity Method Investment After Tax OciEquityMethodInvestmentAfterTax	-7000	usd
	us-gaap	Oci Equity Method Investment After Tax OciEquityMethodInvestmentAfterTax	-24000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-198000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-207000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-323000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-489000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.93
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1220569717	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27273	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	613670159	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27273	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	450000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-489000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-843000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-368000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	98000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	509000	usd
	fdoc	Effect Of Reverse Merger EffectOfReverseMerger	-24000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	501000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-323000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	393000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-316000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-465000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	11000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	8000	usd
	us-gaap	Interest Income Interest Earning Asset InterestIncomeInterestEarningAsset	1000	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-24000	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	6000	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-20000	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	138000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-58000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	62000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	11000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	130000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-342000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-126000	usd
	fdoc	Grant Of Loan To Shareholder GrantOfLoanToShareholder	36000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	501000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	91000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	592000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	250000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-162000	usd
CY2023Q2	fdoc	Effect Of Changes In Foreign Exchange Rates EffectOfChangesInForeignExchangeRates	1000	usd
CY2023Q2	fdoc	Effect Of Reverse Mergers EffectOfReverseMergers	-24000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	254000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5000	usd
	us-gaap	Stock Issued1 StockIssued1	509000	usd
	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	11000	usd
CY2023Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	921750000	shares
CY2023Q2	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	921750000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	922500000	shares
CY2023Q2	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	136500000	shares
CY2023Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify; font-size: 10pt"> </td> <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to shares based compensation and Going concern.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify; font-size: 10pt"></td> <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of credit risks:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and restricted bank deposit. Cash and cash equivalents and restricted bank deposit are invested in major banks in Israel and the United States. Such funds in the Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company and its subsidiary’ cash and cash equivalents have high credit ratings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The Company, have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>
CY2023Q2	us-gaap	Defined Benefit Plan Funded Percentage DefinedBenefitPlanFundedPercentage	0.50	pure
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1188000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1504000	usd
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.1999	pure
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	340	usd
CY2022Q3	us-gaap	Participating Mortgage Loans Participation Liabilities Amount ParticipatingMortgageLoansParticipationLiabilitiesAmount	1000	usd
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	61	usd
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	217000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-42000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses	-23000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	152000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-11000	usd
	us-gaap	Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses	-8000	usd
CY2023Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	133000	usd
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	74000	usd
CY2022Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	74000	usd
	us-gaap	Additions To Other Assets Amount AdditionsToOtherAssetsAmount	11000	usd
CY2023Q2	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	85000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	66000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	595000	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	550	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.0242	pure
CY2023Q1	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	Pursuant to the Medigus Loan Agreement, the interest rate remains unchanged, and the capital and interest will be repaid in cash or shares, or a combination thereof by the earlier of (i) the completion of the Medigus Transaction or (ii) June 30, 2023. On April 4, 2023, the Medigus Loan balance owing was $553. $509 of the Medigus Loan was converted into 28 shares of Charging Robotics and the balance will be repaid in cash.
CY2021Q4	fdoc	Monthly Fees MonthlyFees	24700	ils
CY2021Q4	fdoc	Monthly Fees MonthlyFees	7	usd
CY2021Q4	fdoc	Stock Options Percentage StockOptionsPercentage	0.03	pure
CY2021Q4	us-gaap	Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital	10000	usd
CY2023Q2	us-gaap	Investment Owned Underlying Face Amount At Market Value InvestmentOwnedUnderlyingFaceAmountAtMarketValue	42	usd
CY2022Q2	us-gaap	Investment Owned Underlying Face Amount At Market Value InvestmentOwnedUnderlyingFaceAmountAtMarketValue	42	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1372656029	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	27273	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.0001
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	91000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	28	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	7636	shares
CY2023Q1	fdoc	Percentage Of Shares Issued And Outstanding PercentageOfSharesIssuedAndOutstanding	0.7288	pure
CY2023Q2	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	501000	usd
CY2022Q1	fdoc	Stock Options Granted StockOptionsGranted	30000	usd
CY2022Q1	us-gaap	Share Price SharePrice	7410
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0048	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8333
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6818
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	18	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8333
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	22	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	18	shares
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q2	us-gaap	Other General Expense OtherGeneralExpense		usd
CY2022Q2	us-gaap	Other General Expense OtherGeneralExpense		usd
	us-gaap	Other General Expense OtherGeneralExpense		usd
	us-gaap	Other General Expense OtherGeneralExpense		usd
	us-gaap	Interest Income Interest Earning Asset InterestIncomeInterestEarningAsset		usd
	fdoc	Grant Of Loan To Shareholder GrantOfLoanToShareholder		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q2	fdoc	Effect Of Changes In Foreign Exchange Rates EffectOfChangesInForeignExchangeRates		usd
CY2022Q2	fdoc	Effect Of Reverse Mergers EffectOfReverseMergers		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice		usd
CY2022	us-gaap	Additions To Other Assets Amount AdditionsToOtherAssetsAmount		usd
CY2023Q2	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding		shares
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
	dei	Entity Central Index Key EntityCentralIndexKey	0001459188

Files In Submission

Name	View Source	Status
0001213900-23-068190-index-headers.html	Edgar Link	pending
0001213900-23-068190-index.html	Edgar Link	pending
0001213900-23-068190.txt	Edgar Link	pending
0001213900-23-068190-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_fueldoctor.htm	Edgar Link	pending
f10q0623ex31-2_fueldoctor.htm	Edgar Link	pending
f10q0623ex32-1_fueldoctor.htm	Edgar Link	pending
f10q0623ex32-2_fueldoctor.htm	Edgar Link	pending
f10q0623_fueldoctor.htm	Edgar Link	pending
fdoc-20230630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
fdoc-20230630_cal.xml	Edgar Link	unprocessable
fdoc-20230630_pre.xml	Edgar Link	unprocessable
fdoc-20230630_lab.xml	Edgar Link	unprocessable
fdoc-20230630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_fueldoctor_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHEV
Charging Robotics Inc. Stock $chev

2023 Q3 Form 10-Q Financial Statement

#000121390023068190 Filed on August 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHEV Charging Robotics Inc. Stock $chev

2023 Q3 Form 10-Q Financial Statement

#000121390023068190 Filed on August 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHEV
Charging Robotics Inc. Stock $chev